
The Size Curve Now Depends on Who Keeps Taking the Drug
Beige Plus, a London plus-size boutique, has closed, and its chief executive says GLP-1 drugs cut revenue by 38% in two years. About half of Danish semaglutide starters had stopped within a year, and trial data show most of the weight returns once users stop, so a size range cut on 2025's sales is a bet on drug adherence that sales data cannot see.
Admiral Neritus Vale
Beige Plus sold luxury plus-size womenswear in Marylebone for 24 years and closed on 30 September, which its chief executive blames largely on customers getting smaller. The clinical record says that for many users the shrinkage does not last. A size range bought this autumn is therefore a bet on who keeps taking the drug, a variable that appears in no retailer’s sales history. Hennie Fearnley told Drapers that GLP-1 drugs cut revenue by 38% in two years, because they “were for the wealthy, who are our client base”. She also cited lost VAT refunds for tourists, fewer Middle Eastern shoppers because of the war in Iran, and a landlord who forced her hand.
The shift is reaching size ranges. UCL researchers estimate that about 1.6 million British adults used a GLP-1 drug to lose weight in the year to early 2025, most of them privately, the authors infer from IQVIA data. Use was more common among women and people in mid-life, which suggests womenswear feels it first. Deryane Tadd, who owns The Dressing Room in St Albans, says in Drapers that some key customers who were an M or L now buy XS, and that some denim scales now start at a 23-inch waist. Kantar, which studies GLP-1 users worldwide, notes in the same piece that certain retailers are reducing their size ranges. Timpson has reported a 680% rise in requests for new belt holes, Drapers reports.
The advice reaching buyers is to follow the shift faster. Paul Heywood, a former Adidas running merchandising director, said in the same analysis that “normally brands would buy based on what was sold in the previous year”; he wants more frequent, more detailed conversations with retailers and suggests brands could consider shorter lead-time sourcing. Impact Analytics, which sells AI planning software, writes in a white paper on the US market published this year: “The apparel industry is not facing temporary volatility. It is facing demand re-segmentation.” The paper’s outlook is conditional on GLP-1 adoption continuing to scale, and its first recommendation for 2026 and 2027 is to rebuild the size baseline on 2025’s distributions, with continuous monitoring to follow. Nowhere does it mention users stopping the drug. Kantar is more careful, warning against a retreat from inclusive sizing partly because some users “may regain weight if treatment changes or ends”.
The clinical literature puts a timetable on that regain, starting with how soon people stop. A nationwide Danish cohort published in JAMA Network Open in August found that 49% of people starting semaglutide for weight loss had stopped within twelve months. The range was 45% to 58%, depending on how long a gap counted as stopping. Denmark does not reimburse the drug, so users pay for it themselves.
That makes Denmark a useful guide to Britain’s private market, though an imperfect one. The cohort followed semaglutide users from December 2022 to November 2024, before tirzepatide launched in Denmark, while 80.2% of exclusive weight-loss users in the UCL survey took Mounjaro, which contains tirzepatide. One in four people who stopped restarted within three months, which the authors say may reflect temporary interruptions or self-adjusted dosing. The cohort also held no weight data, so it counts stoppers without measuring how much any of them lost.
Trial data show that people who stop the drug regain much of the weight within a year. Fearnley said in the same Drapers analysis that she had spoken to several customers in the past week who had gained the weight back. In an exploratory follow-up to the STEP 1 trial, people taken off semaglutide after more than a year of treatment had regained two-thirds of their prior weight loss a year later. On our arithmetic, Fearnley’s example of a size 24 who got down to an 18 would be back in a 22, if dress size tracked weight.
The newer drugs have a longer projected timetable. The Oxford review in The BMJ projects that people who stop semaglutide or tirzepatide return to their starting weight 1.5 years later, with a 95% confidence interval of 1.0 to 1.9 years. For these drugs the estimate rests on trials with a mean treatment of about 39 weeks, and the projection extends the model’s trend past 52 weeks of follow-up. Real-world users on the drug for years fall outside it.
On those timetables, regain could fall inside the seasons being bought now. Tadd first noticed the shift eighteen months ago, and it has only now come through into her buy. If British starters behave like Denmark’s, about half of that first wave will have stopped, and on the Oxford projection those who stopped earliest could be most of the way back. The earliest stoppers may have lost too little to change size, so the group that matters is the one that stopped after sizing down. Orders placed this autumn for next season would then meet those customers on the way back. Neither a faster buying cycle nor a 2025 baseline records when a customer stops, and the stop date sets when the regain begins.
Planning software that works from the sizes on offer makes a deleted size hard to bring back. Anaplan, which sells such software, says most retail planning systems “calculate size curves directly from sales data”. Its own machine-learning model corrects for stockout bias so that high-demand sizes stay visible, but it “only considers available sizes”, which the company presents as a safeguard: “There’s no hallucinating demand for sizes that aren’t in the assortment.” That guard is sensible for a size a retailer never offered. Anaplan does not describe a retailer that has cut sizes on purpose; extending its logic to that case is our inference, that a model confined to offered sizes has no way to ask for the 18s and 20s back, however many customers regain.
A size that is not on the rail cannot record the customer who comes back for it.
The strongest objection is that the national curve can keep falling even while individual customers climb back. New users are still arriving: the MHRA approved semaglutide tablets for weight loss in June, and UCL found that 3.3 million more British adults said in a January to March 2025 survey that they were very or fairly likely to consider such a drug in the next year. If starters keep outnumbering quitters, the large sizes lose share for years, and a buyer who cuts them is reading the trend correctly. Tadd adds a version of her own: weight-loss drugs have brought new customers into her shop who could not shop there before, because she did not go beyond L or XL.
That objection rests on a forecast of who starts the drug and who stays on it, which is the variable no sales history records. The inflow also points away from Beige Plus’s clientele. The UCL paper finds no notable overall differences in use by socioeconomic markers and higher interest among disadvantaged groups, while Fearnley’s customers were the wealthy. In the Danish cohort, at least 41% of every group the researchers examined had stopped within a year, including residents of the richest municipalities.
We would thin the large sizes rather than delete them. A thinned size stays in the data, so the till and the model can register customers as they regain. Deletion is also hard to reverse: Fearnley counts at least a dozen luxury plus-size suppliers that have closed in recent years, so a buyer who wants those sizes back may find fewer makers. A buyer who deletes the large sizes this autumn is betting that the customer who shrank will stay shrunk after the prescription lapses.